Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Breakthrough Bloodstream Infections Caused by Echinocandin-Resistant Candida tropicalis: An Emerging Threat to Immunocompromised Patients with Hematological Malignancies.

Sfeir MM, Jiménez-Ortigosa C, Gamaletsou MN, Schuetz AN, Soave R, Besien KV, Small CB, Perlin DS, Walsh TJ.

J Fungi (Basel). 2020 Jan 31;6(1). pii: E20. doi: 10.3390/jof6010020.

2.

A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract.

Marty FM, Chemaly RF, Mullane KM, Lee DG, Hirsch HH, Small CB, Bergeron A, Shoham S, Ljungman P, Waghmare A, Blanchard E, Kim YJ, McKevitt M, Porter DP, Jordan R, Guo Y, German P, Boeckh M, Watkins TR, Chien JW, Dadwal SS.

Clin Infect Dis. 2019 Dec 3. pii: ciz1167. doi: 10.1093/cid/ciz1167. [Epub ahead of print]

3.

A phase 2, randomized, double-blind, placebo-controlled trial of presatovir for the treatment of respiratory syncytial virus upper respiratory tract infection in hematopoietic-cell transplant recipients.

Chemaly RF, Dadwal SS, Bergeron A, Ljungman P, Kim YJ, Cheng GS, Pipavath SN, Limaye AP, Blanchard E, Winston DJ, Stiff PJ, Zuckerman T, Lachance S, Rahav G, Small CB, Mullane KM, Patron RL, Lee DG, Hirsch HH, Waghmare A, McKevitt M, Jordan R, Guo Y, German P, Porter DP, Gossage DL, Watkins TR, Marty FM, Chien JW, Boeckh M.

Clin Infect Dis. 2019 Dec 3. pii: ciz1166. doi: 10.1093/cid/ciz1166. [Epub ahead of print]

4.

Impact of a Multiplexed PCR Panel on Identifying Diarrheal Pathogens in Hematopoietic Cell Transplant Recipients.

Rogers WS, Westblade LF, Soave R, Jenkins SG, van Besien K, Singh HK, Walsh TJ, Small CB, Shore T, Crawford CV, Satlin MJ.

Clin Infect Dis. 2019 Nov 5. pii: ciz1068. doi: 10.1093/cid/ciz1068. [Epub ahead of print]

PMID:
31687767
5.

Clarifying the HOPE Act landscape: The challenge of donors with false-positive HIV results.

Durand CM, Werbel W, Doby B, Brown D, Desai NM, Malinis M, Price J, Chin-Hong P, Mehta S, Friedman-Moraco R, Turgeon NA, Gilbert A, Morris MI, Stosor V, Elias N, Aslam S, Santos CAQ, Hand JM, Husson J, Pruett TL, Agarwal A, Adebiyi O, Pereira M, Small CB, Apewokin S, Heun Lee D, Haidar G, Blumberg E, Mehta SA, Huprikar S, Florman SS, Redd AD, Tobian AAR, Segev DL.

Am J Transplant. 2020 Feb;20(2):617-619. doi: 10.1111/ajt.15681. Epub 2019 Nov 20. No abstract available.

PMID:
31675457
6.

Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk.

Van Besien K, Bachier-Rodriguez L, Satlin M, Brown MA, Gergis U, Guarneri D, Hsu J, Phillips AA, Mayer SA, Singh AD, Soave R, Rossi A, Small CB, Walsh TJ, Rennert H, Shore TB.

Leuk Lymphoma. 2019 Jul;60(7):1693-1696. doi: 10.1080/10428194.2018.1543877. Epub 2019 Feb 10.

PMID:
30741059
7.

Incidence, significance, and persistence of human coronavirus infection in hematopoietic stem cell transplant recipients.

Eichenberger EM, Soave R, Zappetti D, Small CB, Shore T, van Besien K, Douglass C, Westblade LF, Satlin MJ.

Bone Marrow Transplant. 2019 Jul;54(7):1058-1066. doi: 10.1038/s41409-018-0386-z. Epub 2018 Nov 1.

8.

Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.

Robertson K, Maruff P, Ross LL, Wohl D, Small CB, Edelstein H, Shaefer MS.

J Neurovirol. 2019 Feb;25(1):22-31. doi: 10.1007/s13365-018-0680-y. Epub 2018 Oct 8.

9.

Colonization With Levofloxacin-resistant Extended-spectrum β-Lactamase-producing Enterobacteriaceae and Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients.

Satlin MJ, Chavda KD, Baker TM, Chen L, Shashkina E, Soave R, Small CB, Jacobs SE, Shore TB, van Besien K, Westblade LF, Schuetz AN, Fowler VG Jr, Jenkins SG, Walsh TJ, Kreiswirth BN.

Clin Infect Dis. 2018 Nov 13;67(11):1720-1728. doi: 10.1093/cid/ciy363.

10.

Mycobacterial spindle cell pseudotumour: epidemiology and clinical outcomes.

Sfeir MM, Schuetz A, Van Besien K, Borczuk AC, Soave R, Jenkins SG, Walsh TJ, Small CB.

J Clin Pathol. 2018 Jul;71(7):626-630. doi: 10.1136/jclinpath-2017-204777. Epub 2018 Jan 24. Review.

PMID:
29367301
11.

Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.

Orrell C, Hagins DP, Belonosova E, Porteiro N, Walmsley S, Falcó V, Man CY, Aylott A, Buchanan AM, Wynne B, Vavro C, Aboud M, Smith KY; ARIA study team.

Lancet HIV. 2017 Dec;4(12):e536-e546. doi: 10.1016/S2352-3018(17)30095-4. Epub 2017 Jul 17. Erratum in: Lancet HIV. 2017 Dec;4(12 ):e535.

PMID:
28729158
12.

Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial.

Rockstroh JK, Plonski F, Bansal M, Fätkenheuer G, Small CB, Asmuth DM, Pialoux G, Zhang-Roper R, Wang R, Pineda JA, Heera J.

Antivir Ther. 2017;22(3):263-269. doi: 10.3851/IMP3116. Epub 2016 Dec 7.

13.

Corrigendum. Hepatic Safety in Subjects With HIV-1 and Hepatitis C and/or B Virus: A Randomised, Double-Blind Study of Maraviroc vs Placebo in Combination With Antiretroviral Agents.

Rockstroch JK, Soriano V, Plonski F, Bansal M, Fätkenheuer G, Small CB, Asmuth DM, Pialoux G, Mukwaya G, Jagannatha S, Heera J, Pineda JA.

HIV Clin Trials. 2015 Nov;16(6):236-7. doi: 10.1080/15284336.2015.1124625. No abstract available.

PMID:
26777796
14.

Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents.

Rockstroh JK, Soriano V, Plonski F, Bansal M, Fätkenheuer G, Small CB, Asmuth DM, Pialoux G, Mukwaya G, Jagannatha S, Heera J, Pineda JA.

HIV Clin Trials. 2015 Mar-Apr;16(2):72-80. doi: 10.1179/1528433614Z.0000000011. Erratum in: HIV Clin Trials. 2015 Nov;16(6):236-8.

15.

Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial.

Wohl DA, Bhatti L, Small CB, Edelstein H, Zhao HH, Margolis DA, DeJesus E, Weinberg WG, Ross LL, Shaefer MS.

PLoS One. 2014 May 13;9(5):e96187. doi: 10.1371/journal.pone.0096187. eCollection 2014. Erratum in: PLoS One. 2014;9(7):e103925. Dosage error in article text.

16.

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, Hagins D, Felizarta F, Madruga J, Reuter T, Newman T, Small CB, Lombaard J, Grinsztejn B, Dorey D, Underwood M, Griffith S, Min S; extended SAILING Study Team.

Lancet. 2013 Aug 24;382(9893):700-8. doi: 10.1016/S0140-6736(13)61221-0. Epub 2013 Jul 3. Erratum in: Lancet. 2014 Jan 4;383(9911):30.

PMID:
23830355
17.

Safety of mometasone furoate nasal spray in the treatment of nasal polyps in children.

Chur V, Small CB, Stryszak P, Teper A.

Pediatr Allergy Immunol. 2013 Feb;24(1):33-8. doi: 10.1111/pai.12032.

PMID:
23331528
18.

Relationship of serum immunoglobulin and IgG subclass levels to race, ethnicity and behavioral characteristics in HIV infection.

McGowan JP, Shah SS, Small CB, Klein RS, Schnipper SM, Chang CJ, Rosenstreich DL.

Med Sci Monit. 2006 Jan;12(1):CR11-16. Epub 2005 Dec 19.

PMID:
16369464

Supplemental Content

Loading ...
Support Center